|
MechanismMIRN122 microRNA inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
|
MechanismMIRN122 microRNA inhibitors [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
|
MechanismMIRN122 microRNA inhibitors [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
/ Not yet recruitingPhase 2 An Observational Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Have Previously Received RG-101
/ Not yet recruitingPhase 2 A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, or 12 Weeks in Treatment Naïve, Genotype 1 and 3, Chronic Hepatitis C Patients
/ Not yet recruitingPhase 2 A Randomized, Multi-Center, Phase 2 Study to Evaluate Safety and Efficacy of Subcutaneous Injections of RG-101 in Combination with Oral Agents in Treatment Naïve, Genotype 1 and 4, Chronic Hepatitis C Patients
100 Clinical Results associated with MIRN122 microRNA
100 Translational Medicine associated with MIRN122 microRNA
0 Patents (Medical) associated with MIRN122 microRNA